Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

A novel method of immunosuppressive therapy using antibody-conjugated porphyrin-lipid shell microbubbles for drug delivery

EF 2013-14

Résumé
Immunosuppressive therapy is a life-long treatment necessary for preventing transplant rejection in transplant patients. The current method of immunosuppression involves intravenous injection of immunosuppressive drugs in a patient, exposing the patient’s whole body to these drugs. While immunosuppressive drugs prevent short-term rejection of transplants, they are ineffective in preventing long-term transplant rejection. Furthermore, they have been shown to be severely toxic and linked to cancer in a number of transplantation profiles. Therefore, there exists an urgent need for a method of immunosuppression that effectively prevents long-term graft rejection without globally exposure of the body to these toxic drugs. Our lab has recently developed a novel and unique microbubble--a protein or lipid shell encapsulating a fluorinated gas--that is composed of a porphyrin-lipid shell. Unlike other conventional microbubbles, this porphyrin-lipid microbubble can be visualized using ultrasound, photoacoustic, and fluorescent imaging. I propose a novel method of immunosuppression using porphyrin-lipid microbubbles as a delivery vehicle for immunosuppressive drugs. Immunosuppressive drugs will be loaded inside of the porphyrin-lipid microbubbles, which are then coated with antibodies specific for transplant tissue. When the microbubbles are intravenously injected into a patient, they preferentially accumulate at the site of the transplant due to their antibody specificity. A high intensity ultrasound will then be delivered to the graft site, bursting the microbubbles and releasing the drug in the targeted area near the transplant. Each step in this process can be visualized by each of three porphyrin-lipid microbubble imaging modalities, ensuring that immunosuppressive drugs target the transplant without subjecting the rest of the body to extreme toxicity. This new method of immunosuppression will increase both efficacy and tolerability of immunosuppressants, resulting in improved long-term transplant survival and enhanced quality of life for transplant patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311771
Name
So Clare C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A novel method of immunosuppressive therapy using antibody-conjugated porphyrin-lipid shell microbubbles for drug delivery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibodies; Drug Delivery; Imaging; Immunosuppression; Microbubbles; Porphyrin; Toxicity; Transplantation
Abstract
Immunosuppressive therapy is a life-long treatment necessary for preventing transplant rejection in transplant patients. The current method of immunosuppression involves intravenous injection of immunosuppressive drugs in a patient, exposing the patient’s whole body to these drugs. While immunosuppressive drugs prevent short-term rejection of transplants, they are ineffective in preventing long-term transplant rejection. Furthermore, they have been shown to be severely toxic and linked to cancer in a number of transplantation profiles. Therefore, there exists an urgent need for a method of immunosuppression that effectively prevents long-term graft rejection without globally exposure of the body to these toxic drugs. Our lab has recently developed a novel and unique microbubble--a protein or lipid shell encapsulating a fluorinated gas--that is composed of a porphyrin-lipid shell. Unlike other conventional microbubbles, this porphyrin-lipid microbubble can be visualized using ultrasound, photoacoustic, and fluorescent imaging. I propose a novel method of immunosuppression using porphyrin-lipid microbubbles as a delivery vehicle for immunosuppressive drugs. Immunosuppressive drugs will be loaded inside of the porphyrin-lipid microbubbles, which are then coated with antibodies specific for transplant tissue. When the microbubbles are intravenously injected into a patient, they preferentially accumulate at the site of the transplant due to their antibody specificity. A high intensity ultrasound will then be delivered to the graft site, bursting the microbubbles and releasing the drug in the targeted area near the transplant. Each step in this process can be visualized by each of three porphyrin-lipid microbubble imaging modalities, ensuring that immunosuppressive drugs target the transplant without subjecting the rest of the body to extreme toxicity. This new method of immunosuppression will increase both efficacy and tolerability of immunosuppressants, resulting in improved long-term transplant survival and enhanced quality of life for transplant patients.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
So, Clare C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~